Satellite Symposium - Advancing the Management of Urothelial Cancer With Immuno-Oncology and Targeted Approaches: Key Concepts for Urology Professionals on the Front Lines of Care
Registration and Dinner - 5:30 - 6:00 pm
Scientific Session - 6:00 - 7:30 pm
The therapeutic landscape of advanced urothelial carcinoma of the bladder has undergone significant transformation in the last 2 years, with the emergence of immune checkpoint inhibitors as an essential component of the treatment armamentarium. Clinical investigations are underway to further refine and expand the role of this class of agents through combination strategies and across earlier disease settings. Furthermore, extensive research is focusing on newer approaches, such as antibody–drug conjugates and FGFR inhibitors, against actionable targets on urothelial cancer cells. This rapid expansion in the field poses several challenges for urologists and other healthcare professionals who are essential to the multidisciplinary team managing patients with urothelial cancer. Many questions arise in the use of novel agent classes for management of bladder cancer patients: How do we select patients for therapy? What are the unique safety issues, and how do we manage them? What does the future hold as newer approaches are explored? And, finally, how can we maximize the ability of the patient to fully participate in his or her care?
In this PeerView MasterClass Live symposium, a panel of bladder cancer experts will address these questions via focused educational sessions reviewing the science on emerging therapies and latest evidence on immunotherapeutic and targeted strategies for urothelial cancers combined with practical, interactive segments offering the urologist's perspective on achieving optimal outcomes through appropriate counseling and education of patients, as well as effective collaboration and coordination of care among different specialists, including urologists and oncologists. Join us for this CME-certified educational activity!
CME Credit Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Penn State College of Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported through educational grants from Astellas and Seattle Genetics, Bristol-Myers Squibb, Genentech, Incyte Corporation, and Merck & Co., Inc."
Register here: PeerView.com/UroBladder19